Vol. 3, Issue 2 (2017)
A study on hepatitis-B in pregnant women and their neonatal outcome
Author(s): Dr. Supriya Sharma, Dr. Gaurav Pandey, Dr. Seema Choudhary, Dr. Arvind Kumar Choudhary, Dr. Sushma Pandey
Abstract: Chronic hepatitis B virus (HBV) infection remains an important worldwide cause of chronic liver disease, which may lead to the development of cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. It is estimated that 2 billion people worldwide have been infected with HBV, 350 million of whom are chronically infected, with 50 million new cases diagnosed annually, despite the availability of an effective and safe vaccination. In the United States, the overall prevalence of HBV infection is 1.25 million, 1 which may not account for some high-risk groups that would increase this estimate to 2 million.2 The prevalence of HBV infection varies greatly in different regions of the world, with rates of detectable hepatitis B surface antigen (HBsAg) ranging from 15% in highly endemic areas such as sub-Saharan Africa, Asia (excluding Japan), the Pacific Basin, parts of the Middle East, and the Amazon Basin to less than 2% in North America and western Europe. In areas of low endemicity, immigration patterns contribute to local variability in prevalence rates of HBV infection, particularly in communities with a large number of immigrants from highly endemic areas, many of whom may be women of childbearing age.